JP2011520810A - Ｃ型肝炎の治療のための７ｈ−インドロ［２，１−ａ］［２］ベンゾアゼピン−１０−カルボン酸誘導体 - Google Patents
Ｃ型肝炎の治療のための７ｈ−インドロ［２，１−ａ］［２］ベンゾアゼピン−１０−カルボン酸誘導体 Download PDFInfo
- Publication number
- JP2011520810A JP2011520810A JP2011508593A JP2011508593A JP2011520810A JP 2011520810 A JP2011520810 A JP 2011520810A JP 2011508593 A JP2011508593 A JP 2011508593A JP 2011508593 A JP2011508593 A JP 2011508593A JP 2011520810 A JP2011520810 A JP 2011520810A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- solvent
- cyclohexyl
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *C1(*2)C2c(cccc2)c2-c2c(*)c3ccc(*)cc3[n]2C1 Chemical compound *C1(*2)C2c(cccc2)c2-c2c(*)c3ccc(*)cc3[n]2C1 0.000 description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- SJMCLWCCNYAWRQ-UHFFFAOYSA-N CC(C)S(N)(=O)=O Chemical compound CC(C)S(N)(=O)=O SJMCLWCCNYAWRQ-UHFFFAOYSA-N 0.000 description 2
- QMHAHUAQAJVBIW-UHFFFAOYSA-N CN(C)S(N)(=O)=O Chemical compound CN(C)S(N)(=O)=O QMHAHUAQAJVBIW-UHFFFAOYSA-N 0.000 description 2
- OQMSHITZFTVBHN-UHFFFAOYSA-N CN1CC(CC2)NC2C1 Chemical compound CN1CC(CC2)NC2C1 OQMSHITZFTVBHN-UHFFFAOYSA-N 0.000 description 2
- IPJRIKVVQURIDV-IOXBOXJCSA-N CC(C)C/C(/N(CC(c([n](C1CCC1)nc1)c1C(N1C2CN(C)CC1CC2)=O)=Cc1c2ccc(OC)c1)C2=C)=C\C Chemical compound CC(C)C/C(/N(CC(c([n](C1CCC1)nc1)c1C(N1C2CN(C)CC1CC2)=O)=Cc1c2ccc(OC)c1)C2=C)=C\C IPJRIKVVQURIDV-IOXBOXJCSA-N 0.000 description 1
- LFYMJSMTGOHTMP-AERZKKPOSA-N CC(C)C/C(/N(CC(c([n](C1CCC1)nc1)c1C(O)=O)=Cc1c2ccc(OC)c1)C2=C)=C\C Chemical compound CC(C)C/C(/N(CC(c([n](C1CCC1)nc1)c1C(O)=O)=Cc1c2ccc(OC)c1)C2=C)=C\C LFYMJSMTGOHTMP-AERZKKPOSA-N 0.000 description 1
- DMZXYWAYGVYUDX-UHFFFAOYSA-N CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4C5CN(C)CC4CC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4C5CN(C)CC4CC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O DMZXYWAYGVYUDX-UHFFFAOYSA-N 0.000 description 1
- VBEDDVYPQUUFGY-UHFFFAOYSA-N CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCOCC4)nc4)c4C(N4C5CN(C)CC4CC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCOCC4)nc4)c4C(N4C5CN(C)CC4CC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O VBEDDVYPQUUFGY-UHFFFAOYSA-N 0.000 description 1
- OHVLGQJDRJVHSJ-RNPORBBMSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](-c4c(C)cncc4)nc4)c4C(N4C[C@H](C)N(C)[C@H](C)C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](-c4c(C)cncc4)nc4)c4C(N4C[C@H](C)N(C)[C@H](C)C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O OHVLGQJDRJVHSJ-RNPORBBMSA-N 0.000 description 1
- UWIMADCFLWWEHH-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4CC(CC5)N(C)C5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4CC(CC5)N(C)C5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O UWIMADCFLWWEHH-UHFFFAOYSA-N 0.000 description 1
- SKSKDJDHBIUVBI-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCN(C)CC4)nc4)c4C(N4C5COCC4COC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCN(C)CC4)nc4)c4C(N4C5COCC4COC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O SKSKDJDHBIUVBI-UHFFFAOYSA-N 0.000 description 1
- ZDNMJDOLJFUJQF-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(N5CCOCC5)=O)[n](C5CC5)cn4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(N5CCOCC5)=O)[n](C5CC5)cn4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O ZDNMJDOLJFUJQF-UHFFFAOYSA-N 0.000 description 1
- PNHQKARQANCHAV-MKPDMIMOSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(N5C[C@H](C)O[C@H](C)C5)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(N5C[C@H](C)O[C@H](C)C5)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O PNHQKARQANCHAV-MKPDMIMOSA-N 0.000 description 1
- USXPUFDBCXAXIG-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(O)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(O)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O USXPUFDBCXAXIG-UHFFFAOYSA-N 0.000 description 1
- UIFXXNPSMPQPHW-UHFFFAOYSA-N CC(C)c1n[n](C2CC2)c(C(C[n]2c3c4)=Cc(cc(cc5)OC)c5-c2c(C2CCCCC2)c3ccc4C(NS(C(C)C)(=O)=O)=O)c1C(N1C2CN(C)CC1CC2)=O Chemical compound CC(C)c1n[n](C2CC2)c(C(C[n]2c3c4)=Cc(cc(cc5)OC)c5-c2c(C2CCCCC2)c3ccc4C(NS(C(C)C)(=O)=O)=O)c1C(N1C2CN(C)CC1CC2)=O UIFXXNPSMPQPHW-UHFFFAOYSA-N 0.000 description 1
- SMZHAAHALVBANZ-YCPBAFNGSA-N CC/C=C(\C(C)(C)C)/N(CC(c([n](C1CCC1)nc1)c1C(O)=O)=Cc1c2ccc(OC)c1)C2=C Chemical compound CC/C=C(\C(C)(C)C)/N(CC(c([n](C1CCC1)nc1)c1C(O)=O)=Cc1c2ccc(OC)c1)C2=C SMZHAAHALVBANZ-YCPBAFNGSA-N 0.000 description 1
- NZXZPEGCOJXYEV-RNFRBKRXSA-N CCN(C1)[C@@]2(C3)[C@]13NC2 Chemical compound CCN(C1)[C@@]2(C3)[C@]13NC2 NZXZPEGCOJXYEV-RNFRBKRXSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N CCN(CC)CC Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- UATBCOJAMOONNS-KFPZEKMWSA-N CCN(CC1C2)[C@@H]2CN1C(c1c(C(CN2/C(/C(C)(C)OC)=C/C)=Cc(cc(cc3)OC)c3C2=C)[n](C2CCC2)nc1)=O Chemical compound CCN(CC1C2)[C@@H]2CN1C(c1c(C(CN2/C(/C(C)(C)OC)=C/C)=Cc(cc(cc3)OC)c3C2=C)[n](C2CCC2)nc1)=O UATBCOJAMOONNS-KFPZEKMWSA-N 0.000 description 1
- CJUKORZJVRPBRJ-UHFFFAOYSA-N CCNNC1CCC1 Chemical compound CCNNC1CCC1 CJUKORZJVRPBRJ-UHFFFAOYSA-N 0.000 description 1
- HFZAWIVVQWDCIH-UHFFFAOYSA-N CCNc1cc(C(NS(N(C)C)(=O)=O)=O)ccc1C Chemical compound CCNc1cc(C(NS(N(C)C)(=O)=O)=O)ccc1C HFZAWIVVQWDCIH-UHFFFAOYSA-N 0.000 description 1
- PZIURDJPHISLBX-UHFFFAOYSA-O CCOC(C(C=N)=C(C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(OC(C)(C)C)=O)[NH2+]C1CCOCC1)=O Chemical compound CCOC(C(C=N)=C(C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(OC(C)(C)C)=O)[NH2+]C1CCOCC1)=O PZIURDJPHISLBX-UHFFFAOYSA-O 0.000 description 1
- UVBGKNFXCWOYFZ-XTWGIRIWSA-N CCc(c(NCC(C)(C)[C@@H](C)CC(N1C2CN(C)CC1CC2)=O)c1)ccc1C(NS(N(C)C)(=O)=O)=O Chemical compound CCc(c(NCC(C)(C)[C@@H](C)CC(N1C2CN(C)CC1CC2)=O)c1)ccc1C(NS(N(C)C)(=O)=O)=O UVBGKNFXCWOYFZ-XTWGIRIWSA-N 0.000 description 1
- DZBRHAQYCSQDOO-UHFFFAOYSA-N CN(C)C(ON1NN(C)c2c1cccc2)=[N+](C)C Chemical compound CN(C)C(ON1NN(C)c2c1cccc2)=[N+](C)C DZBRHAQYCSQDOO-UHFFFAOYSA-N 0.000 description 1
- KXDNXZJINVZOKE-UHFFFAOYSA-N CNNC1CCC1 Chemical compound CNNC1CCC1 KXDNXZJINVZOKE-UHFFFAOYSA-N 0.000 description 1
- CVXDXXOYWXXYSX-UHFFFAOYSA-N COC1=CCCC=C1 Chemical compound COC1=CCCC=C1 CVXDXXOYWXXYSX-UHFFFAOYSA-N 0.000 description 1
- CMXVPHSHKFQSHM-UHFFFAOYSA-N NNC1CCOCC1 Chemical compound NNC1CCOCC1 CMXVPHSHKFQSHM-UHFFFAOYSA-N 0.000 description 1
- JERISWAPEKWWAB-UHFFFAOYSA-N ON1NNc2ccccc12 Chemical compound ON1NNc2ccccc12 JERISWAPEKWWAB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5074308P | 2008-05-06 | 2008-05-06 | |
| US61/050,743 | 2008-05-06 | ||
| PCT/US2009/042805 WO2009137454A1 (en) | 2008-05-06 | 2009-05-05 | 7h-indolo[2,1-a] [2] benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520810A true JP2011520810A (ja) | 2011-07-21 |
| JP2011520810A5 JP2011520810A5 (enExample) | 2012-06-21 |
Family
ID=40786514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508593A Withdrawn JP2011520810A (ja) | 2008-05-06 | 2009-05-05 | Ｃ型肝炎の治療のための７ｈ−インドロ［２，１−ａ］［２］ベンゾアゼピン−１０−カルボン酸誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8133884B2 (enExample) |
| EP (1) | EP2280975B1 (enExample) |
| JP (1) | JP2011520810A (enExample) |
| KR (1) | KR20110015588A (enExample) |
| CN (1) | CN102083834A (enExample) |
| AR (1) | AR071684A1 (enExample) |
| AU (1) | AU2009244409A1 (enExample) |
| BR (1) | BRPI0915130A2 (enExample) |
| CA (1) | CA2723683A1 (enExample) |
| CL (1) | CL2009001089A1 (enExample) |
| CO (1) | CO6290645A2 (enExample) |
| EA (1) | EA201001748A1 (enExample) |
| IL (1) | IL208753A0 (enExample) |
| MX (1) | MX2010011921A (enExample) |
| NZ (1) | NZ588556A (enExample) |
| PE (1) | PE20091879A1 (enExample) |
| TW (1) | TW200951135A (enExample) |
| WO (1) | WO2009137454A1 (enExample) |
| ZA (1) | ZA201007649B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015528008A (ja) * | 2012-07-18 | 2015-09-24 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ | （４ｂＳ，５ａＲ）−１２−シクロヘキシル−Ｎ−（Ｎ，Ｎ−ジメチルスルファモイル）−３−メトキシ−５ａ−（（１Ｒ，５Ｓ）−３−メチル−３，８−ジアザビシクロ［３．２．１］オクタン−８−カルボニル）−４ｂ，５，５ａ，６−テトラヒドロベンゾ［３，４］シクロプロパ［５，６］アゼピノ［１，２−Ａ］インドール−９−カルボキサミドを製造するための新規な方法および中間体 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| KR20100124848A (ko) | 2008-03-27 | 2010-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1719773B1 (en) | 2004-02-24 | 2009-04-15 | Japan Tobacco, Inc. | Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2005298412B2 (en) | 2004-10-26 | 2011-06-09 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| ATE469155T1 (de) | 2006-05-25 | 2010-06-15 | Bristol Myers Squibb Co | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer |
| WO2007140200A2 (en) | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7541351B2 (en) | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7521444B2 (en) | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7547690B2 (en) | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538102B2 (en) | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7541353B2 (en) | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538103B2 (en) | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US20090018163A1 (en) | 2007-07-11 | 2009-01-15 | Bristol-Myers Squibb Company | Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| US7642251B2 (en) | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7652004B2 (en) | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8129367B2 (en) | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
-
2009
- 2009-05-04 US US12/434,748 patent/US8133884B2/en active Active
- 2009-05-05 MX MX2010011921A patent/MX2010011921A/es active IP Right Grant
- 2009-05-05 CA CA2723683A patent/CA2723683A1/en not_active Abandoned
- 2009-05-05 BR BRPI0915130A patent/BRPI0915130A2/pt not_active IP Right Cessation
- 2009-05-05 EA EA201001748A patent/EA201001748A1/ru unknown
- 2009-05-05 NZ NZ588556A patent/NZ588556A/en not_active IP Right Cessation
- 2009-05-05 AU AU2009244409A patent/AU2009244409A1/en not_active Abandoned
- 2009-05-05 PE PE2009000605A patent/PE20091879A1/es not_active Application Discontinuation
- 2009-05-05 WO PCT/US2009/042805 patent/WO2009137454A1/en not_active Ceased
- 2009-05-05 KR KR1020107027222A patent/KR20110015588A/ko not_active Withdrawn
- 2009-05-05 CN CN2009801263266A patent/CN102083834A/zh active Pending
- 2009-05-05 JP JP2011508593A patent/JP2011520810A/ja not_active Withdrawn
- 2009-05-05 EP EP09743440.1A patent/EP2280975B1/en not_active Ceased
- 2009-05-06 AR ARP090101641A patent/AR071684A1/es not_active Application Discontinuation
- 2009-05-06 TW TW098115001A patent/TW200951135A/zh unknown
- 2009-05-06 CL CL2009001089A patent/CL2009001089A1/es unknown
-
2010
- 2010-10-14 IL IL208753A patent/IL208753A0/en unknown
- 2010-10-26 ZA ZA2010/07649A patent/ZA201007649B/en unknown
- 2010-10-28 CO CO10134256A patent/CO6290645A2/es not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015528008A (ja) * | 2012-07-18 | 2015-09-24 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ | （４ｂＳ，５ａＲ）−１２−シクロヘキシル−Ｎ−（Ｎ，Ｎ−ジメチルスルファモイル）−３−メトキシ−５ａ−（（１Ｒ，５Ｓ）−３−メチル−３，８−ジアザビシクロ［３．２．１］オクタン−８−カルボニル）−４ｂ，５，５ａ，６−テトラヒドロベンゾ［３，４］シクロプロパ［５，６］アゼピノ［１，２−Ａ］インドール−９−カルボキサミドを製造するための新規な方法および中間体 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009137454A1 (en) | 2009-11-12 |
| EP2280975A1 (en) | 2011-02-09 |
| KR20110015588A (ko) | 2011-02-16 |
| NZ588556A (en) | 2012-06-29 |
| CA2723683A1 (en) | 2009-11-12 |
| CL2009001089A1 (es) | 2011-04-29 |
| EA201001748A1 (ru) | 2011-06-30 |
| TW200951135A (en) | 2009-12-16 |
| MX2010011921A (es) | 2010-11-30 |
| AR071684A1 (es) | 2010-07-07 |
| EP2280975B1 (en) | 2014-01-01 |
| CN102083834A (zh) | 2011-06-01 |
| AU2009244409A1 (en) | 2009-11-12 |
| PE20091879A1 (es) | 2009-12-19 |
| BRPI0915130A2 (pt) | 2019-09-24 |
| CO6290645A2 (es) | 2011-06-20 |
| ZA201007649B (en) | 2012-04-25 |
| US20090280083A1 (en) | 2009-11-12 |
| US8133884B2 (en) | 2012-03-13 |
| IL208753A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5465670B2 (ja) | Ｃ型肝炎を治療するための化合物 | |
| JP5284952B2 (ja) | シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤 | |
| JP5232178B2 (ja) | Ｃ型肝炎の治療のための化合物 | |
| JP5301473B2 (ja) | Ｃ型肝炎の治療のための化合物 | |
| WO2007033175A1 (en) | Indolobenzazepine hcv ns5b inhibitors | |
| JP2008509218A (ja) | Ｈｃｖ複製の阻害剤 | |
| EP2209789A1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| JP2011520810A (ja) | Ｃ型肝炎の治療のための７ｈ−インドロ［２，１−ａ］［２］ベンゾアゼピン−１０−カルボン酸誘導体 | |
| JP5211078B2 (ja) | シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤 | |
| CA3258118A1 (en) | MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS | |
| EP2396329B1 (en) | Compounds for the treatment of hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120502 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120502 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130624 |